The 3 most recent market catalysts affecting $ACTU, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer Models
The positive preclinical data for the combination of Elraglusib with Zoldonrasib and Daraxonrasib in pancreatic cancer models is a significant corporate catalyst for Actuate Therap…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target
The filing reports that HC Wainwright & Co. analyst Swayampakula Ramakanth has reaffirmed a 'Buy' rating and a $15 price target for Actuate Therapeutics (ACTU). This is a routine a…
Jul 30, 2026
Corporate Catalyst
Neutral
Impact 65
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6
Rodman & Renshaw analyst Michael G. King Jr. has initiated coverage on Actuate Therapeutics (ACTU) with a 'Buy' rating and a $6 price target. This event is significant for ACTU as …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.